Medicare Enrolled
Dr. Jason Melear, M.D.
Medical Oncology · Austin, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Melear from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Melear?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Melear
Dr. Jason Melear is a medical oncology specialist in Austin, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Melear performed 26,799 Medicare services across 2,747 unique beneficiaries.
Between the years covered by Open Payments, Dr. Melear received a total of $239,212 from 45 pharmaceutical and/or device companies across 328 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Melear is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 32% volume in TX
$239,212 industry payments
Medicare Practice Summary
Medicare Utilization ↗26,799
Medicare services
Top 32% in TX for medical oncology
2,747
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,410 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
8,725 | $2 | $20 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
7,300 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 2,580 | $19 | $67 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,099 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
997 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
810 | $8 | $36 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
730 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 520 | $0 | $24 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
428 | $17 | $60 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
346 | $93 | $368 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
327 | $62 | $250 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
194 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
194 | $6 | $34 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
191 | $24 | $157 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
170 | $133 | $496 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
166 | $107 | $707 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
139 | $6 | $31 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
134 | $35 | $143 |
| Serum protein measurement A blood test that measures the total amount of protein in the serum. It helps evaluate overall health and nutritional status. |
125 | $11 | $99 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
113 | $6 | $431 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
105 | $51 | $313 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
103 | $13 | $60 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
102 | $9 | $56 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
89 | $11 | $96 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
89 | $23 | $161 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
87 | $2 | $19 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 81 | $20 | $128 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
76 | $60 | $211 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
74 | $12 | $108 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
70 | $1 | $7 |
| Iron level test | 52 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
52 | $8 | $35 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
52 | $10 | $75 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
50 | $18 | $99 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
49 | $53 | $344 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
48 | $17 | $100 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
42 | $26 | $145 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
35 | $27 | $256 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 35 | $344 | $1,722 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
30 | $46 | $289 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 23 | $90 | $657 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
23 | $1 | $8 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
23 | $1 | $19 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
20 | $31 | $247 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
16 | $118 | $565 |
| New patient office visit, complex (60-74 min) | 16 | $163 | $709 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
15 | $1,229 | $4,802 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $89 | $372 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
14 | $39 | $135 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $136 | $694 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
12 | $72 | $264 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.6% high complexity
77.9% medium
19.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$239,212
Total received (2018-2024)
Avg $34,173/year across 7 years
Top 8% in TX for medical oncology
45
Companies
328
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$205,736 (86.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$30,968 (12.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,508 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$42,180
2023
$27,239
2022
$29,355
2021
$20,161
2020
$12,475
2019
$52,061
2018
$55,740
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$119,606
AstraZeneca Pharmaceuticals LP
$51,363
Janssen Scientific Affairs, LLC
$32,558
AbbVie, Inc.
$7,163
Amgen Inc.
$6,370
Celgene Corporation
$4,651
Epizyme, Inc.,
$3,750
Seagen Inc.
$2,438
Karyopharm Therapeutics Inc.
$1,961
GENZYME CORPORATION
$1,951
NOVARTIS PHARMACEUTICALS CORPORATION
$1,838
AbbVie Inc.
$1,400
BeiGene USA, Inc.
$1,073
Genentech USA, Inc.
$877
E.R. Squibb & Sons, L.L.C.
$240
Novartis Pharmaceuticals Corporation
$221
PFIZER INC.
$148
Lilly USA, LLC
$133
ADC Therapeutics America, Inc.
$127
Seattle Genetics, Inc.
$125
GlaxoSmithKline, LLC.
$123
Genmab U.S., Inc.
$115
Blueprint Medicines Corporation
$100
Covidien LP
$96
Daiichi Sankyo Inc.
$74
Astellas Pharma US Inc
$68
Merck Sharp & Dohme LLC
$65
JAZZ PHARMACEUTICALS INC.
$63
Regeneron Healthcare Solutions, Inc.
$57
Pharmacyclics LLC, An AbbVie Company
$57
Takeda Pharmaceuticals U.S.A., Inc.
$55
Apellis Pharmaceuticals, Inc.
$45
Gilead Sciences, Inc.
$36
Incyte Corporation
$35
Merck Sharp & Dohme Corporation
$33
AVEO Pharmaceuticals, Inc.
$32
CSL Behring
$23
Dova Pharmaceuticals
$23
Taiho Oncology, Inc.
$19
ABBVIE INC.
$18
Stemline Therapeutics Inc.
$18
Eisai Inc.
$18
Tempus AI, Inc
$17
Kite Pharma, Inc.
$17
Bayer HealthCare Pharmaceuticals Inc.
$16
Top 3 companies account for 85.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BRUKINSA · CABLIVI · CALQUENCE · DARZALEX · Doptelet · ELIQUIS · ELREXFIO · ELZONRIS · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FOTIVDA · Fabhalta · HEMGENIX · ICLUSIG · IMBRUVICA · IMFINZI · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · Lonsurf · MEKINIST · NINLARO · Non-Covered Product · OJJAARA · OPDIVO · OXBRYTA · PADCEV · PEMAZYRE · PROMACTA · Padcev · Pomalyst · Prolia · REBLOZYL · RETEVMO · SARCLISA · SCEMBLIX · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · Trodelvy · VENCLEXTA · VERZENIO · VYXEOS · Vanflyta · Venclexta · Vitrakvi · Vyloy · XPOVIO · Xospata · Yescarta · ZEJULA · iDrive
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (86%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for medical oncology in TX.
Equivalent to $893 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
26
Per 100K population
2.0
County median income
$97,169
Nearest hospital
ASCENSION SETON MEDICAL CENTER AUSTIN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Melear is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 8% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Melear experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Melear performed 8,725 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Melear receive payments from pharmaceutical companies?
Yes. Dr. Melear received a total of $239,212 from 45 companies across 328 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Melear's costs compare to other medical oncologists in Austin?
Dr. Melear's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Melear) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Austin
Browse medical oncologists in Austin ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Scientific Affairs, LLC Payments to Doctors
See all physicians who received payments from Janssen Scientific Affairs, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology